Strides Arcolab (Strides) has received ANDA approval from USFDA for Acetazolamide Injection USP, 500 mg/ vial (preservative free) in lyophilized format. The product is expected to be launched shortly. According to IMS, the 2011 US market for Injectable Acetazolamide approximates to $10 million with only one active player.
Acetazolamide is the fourteenth product approved under the Sagent - Strides partnership. Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.
Acetazolamide is used for adjunctive treatment of - edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.
